Contract 75A50123C00021

Lungpacer Medical USA Inc · Department Of Health And Human Services · April 20, 2023

Firm Fixed PriceFull & Open CompetitionNAICS 541714

Lungpacer Medical USA Inc was awarded a federal contract by Department Of Health And Human Services (Office Of Assistant Secretary For Preparedness And Response) on April 20, 2023 for $750,000 of work in research and development in biotechnology (except nanobiotechnology). Performance is in Exton, PA. It was awarded under full and open competition. The contract has been modified 4 times since the base award It uses firm fixed-price contract pricing. The most recent modification was on March 18, 2026.

Obligated to date
$749.8K
$749,796
Current value
$749.8K
Modifications
4
Latest March 18, 2026

Contract details

PIID
75A50123C00021
Award type
Definitive Contract
Pricing
Firm Fixed Price
Set-aside
No Set Aside Used.
Competition
Full And Open Competition
NAICS
541714 · Research And Development In Biotechnology (Except Nanobiotechnology)
Product / service
Health R&D Services; Health Care Services; Experimental Development
Place of performance
Exton, PA
First action
April 20, 2023
Latest action
March 18, 2026

Description

LUNGPACER MEDICAL USA INC LUNG-PROTECTIVE EFFECTS OF TRANSVENOUS DIAPHRAGM ACTIVATION IN PATIENTS WITH ARDS AOI #12: MITIGATING LONG-TERM EFFECTS (MILE) OF RESPIRATORY DISTRESS

Modification timeline

  • March 18, 2026
    Mod P00004
    LUNGPACER MEDICAL USA INC LUNG-PROTECTIVE EFFECTS OF TRANSVENOUS DIAPHRAGM ACTIVATION IN PATIENTS WITH ARDS AOI #12: MITIGATING LONG-TERM EFFECTS (MILE) OF RESP
    $0
  • May 2, 2025
    Mod P00003
    LUNGPACER MEDICAL USA INC LUNG-PROTECTIVE EFFECTS OF TRANSVENOUS DIAPHRAGM ACTIVATION IN PATIENTS WITH ARDS AOI #12: MITIGATING LONG-TERM EFFECTS (MILE) OF RESP
    $0
  • October 8, 2024
    Mod P00002
    LUNGPACER MEDICAL USA INC LUNG-PROTECTIVE EFFECTS OF TRANSVENOUS DIAPHRAGM ACTIVATION IN PATIENTS WITH ARDS AOI #12: MITIGATING LONG-TERM EFFECTS (MILE) OF RESP
    $0
  • September 5, 2023
    Mod P00001
    LUNGPACER MEDICAL USA INC LUNG-PROTECTIVE EFFECTS OF TRANSVENOUS DIAPHRAGM ACTIVATION IN PATIENTS WITH ARDS AOI #12: MITIGATING LONG-TERM EFFECTS (MILE) OF RESP
    $0
  • April 20, 2023
    Base award
    LUNGPACER MEDICAL USA INC LUNG-PROTECTIVE EFFECTS OF TRANSVENOUS DIAPHRAGM ACTIVATION IN PATIENTS WITH ARDS AOI #12: MITIGATING LONG-TERM EFFECTS (MILE) OF RESP
    $749.8K

Similar contracts

RecipientAgencyDateObligated
Vericel CorporationDepartment Of Health And Human ServicesApril 1, 2026$34.88M
Ceramedix Holding, LlcDepartment Of Health And Human ServicesMarch 31, 2026$4.22M
American College Of Medical Toxicology, Inc.Department Of Health And Human ServicesMarch 31, 2026$0
Glaxosmithkline, LlcDepartment Of Health And Human ServicesMarch 31, 2026$7.79M
Care Access Research LlcDepartment Of Health And Human ServicesMarch 31, 2026$2.55M
Pattern Bioscience, Inc.Department Of Health And Human ServicesMarch 31, 2026$22.50M

Top contractors in NAICS 541714

Lifetime obligated dollars across all federal contracts in this NAICS code.

Track this on BesaGov

Get a free weekly email when this changes — new awards, new sub-awards, new opportunities. No login required.

✓ You’re on the list. We’ll never spam you.

Helpful guides

Continue learning

See all guides →
More on BesaGov

Keep researching

Track this contract, set alerts on similar opportunities, and build proposal pipelines on BesaGov.
Sign up free

Frequently asked questions

What is contract 75A50123C00021?

Contract 75A50123C00021 is a federal contract awarded to Lungpacer Medical USA Inc by Department Of Health And Human Services on April 20, 2023 for $750,000 of work classified under RESEARCH AND DEVELOPMENT IN BIOTECHNOLOGY (EXCEPT NANOBIOTECHNOLOGY). It has been modified 4 times since the base award.

Who won contract 75A50123C00021?

Lungpacer Medical USA Inc won contract 75A50123C00021 from Department Of Health And Human Services.

How much is contract 75A50123C00021 worth?

Contract 75A50123C00021 has obligated $750,000 to date.